Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2022. For the year ending December 31, 2022, the Company expects net revenue of between $448 million and $465 million, representing a decrease of approximately 1% to 4% year-over-year, and a decrease of 2% to an increase of 2% on an adjusted basis2, as compared to net revenue of $467.4 million3 for the year ended December 31, 2021. Net income in a range of approximately $12 million to $20 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.495 USD | -4.41% | -9.27% | -39.00% |
May. 13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
May. 10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.00% | 331M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022